Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.36 -0.46 (-0.77%)
Streaming Delayed Price Updated: 12:48 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,152,914
Open 59.82
Bid (Size) 59.35 (6)
Ask (Size) 59.36 (3)
Prev. Close 59.82
Today's Range 58.81 - 60.62
52wk Range 39.35 - 61.08
Shares Outstanding 2,222,113,553
Dividend Yield 3.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet... 
Via Benzinga
Dow, S&P 500 On Track For Milestone Closes
Wall Street is extending its post-election rally into a new week. 
Via Talk Markets
Topics Stocks
Exposures US Equities

Performance

YTD
+12.51%
+12.51%
1 Month
+12.70%
+12.70%
3 Month
+26.14%
+26.14%
6 Month
+31.74%
+31.74%
1 Year
+18.36%
+18.36%

More News

Read More
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
Via Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Via Investor's Business Daily
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
From Bristol Myers Squibb
Via Business Wire
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Via Investor's Business Daily
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Via Benzinga
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
Via Investor's Business Daily
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Markets Give Back Gains As Hovering Continues
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.